N‐Acyl amino acids and N‐acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets
暂无分享,去创建一个
[1] W. S. Ho,et al. N‐arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium‐activated potassium channels , 2010, British journal of pharmacology.
[2] J. Walker,et al. Identification of endogenous acyl amino acids based on a targeted lipidomics approach1[S] , 2010, Journal of Lipid Research.
[3] Robert M. Jones,et al. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. , 2010, Molecular endocrinology.
[4] R. Vandenberg,et al. Extracellular Loops 2 and 4 of GLYT2 Are Required for N-Arachidonylglycine Inhibition of Glycine Transport* , 2009, The Journal of Biological Chemistry.
[5] A. Eschalier,et al. T-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids , 2009, The Journal of Neuroscience.
[6] H. Bradshaw,et al. The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.
[7] H. Bradshaw,et al. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways , 2009, BMC Biochemistry.
[8] J. Caldwell,et al. Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay , 2009, Journal of Biological Chemistry.
[9] James I. Fells,et al. Unique Ligand Selectivity of the GPR92/LPA5 Lysophosphatidate Receptor Indicates Role in Human Platelet Activation* , 2009, The Journal of Biological Chemistry.
[10] M. Connor,et al. Inhibition of human recombinant T‐type calcium channels by the endocannabinoid N‐arachidonoyl dopamine , 2009, British journal of pharmacology.
[11] R. Ross. The enigmatic pharmacology of GPR55. , 2009, Trends in pharmacological sciences.
[12] D. Lovinger,et al. The Endogenous Brain Constituent N-Arachidonoyl l-Serine Is an Activator of Large Conductance Ca2+-Activated K+ Channels , 2009, Journal of Pharmacology and Experimental Therapeutics.
[13] Martin Jones,et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels , 2008, Nucleic Acids Res..
[14] H. Bradshaw,et al. Novel endogenous N-acyl glycines identification and characterization. , 2009, Vitamins and hormones.
[15] J. Walker,et al. Alcohol dehydrogenase-catalyzed in vitro oxidation of anandamide to N-arachidonoyl glycine, a lipid mediator: synthesis of N-acyl glycinals. , 2009, Bioorganic & medicinal chemistry letters.
[16] H. Bradshaw,et al. Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors. , 2009, Prostaglandins & other lipid mediators.
[17] R. Vandenberg,et al. Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. , 2008, Biochemical pharmacology.
[18] S. Ikeda,et al. N-arachidonoyl L-serine, a putative endocannabinoid, alters the activation of N-type Ca2+ channels in sympathetic neurons. , 2008, Journal of neurophysiology.
[19] Min Goo Lee,et al. Identification of Farnesyl Pyrophosphate and N-Arachidonylglycine as Endogenous Ligands for GPR92* , 2008, Journal of Biological Chemistry.
[20] D. McHugh,et al. N-Palmitoyl Glycine, a Novel Endogenous Lipid That Acts As a Modulator of Calcium Influx and Nitric Oxide Production in Sensory Neurons , 2008, Molecular Pharmacology.
[21] M. Connor,et al. Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.
[22] J. A. Lundbæk. Lipid Bilayer–mediated Regulation of Ion Channel Function by Amphiphilic Drugs , 2008, The Journal of general physiology.
[23] É. Szőke,et al. Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. , 2008, Life sciences.
[24] J A Peters,et al. Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.
[25] D. McHugh,et al. Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2 , 2008, Molecular Pharmacology.
[26] C. Vaughan,et al. Actions of N-arachidonyl-glycine in a rat neuropathic pain model , 2008, Neuropharmacology.
[27] W. Driscoll,et al. Cytochrome c catalyzes the in vitro synthesis of arachidonoyl glycine. , 2008, Biochemical and biophysical research communications.
[28] M. Martı́n,et al. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta , 2007, British journal of pharmacology.
[29] S. O'Sullivan,et al. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.
[30] S. Dowell,et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects , 2007, British journal of pharmacology.
[31] D. Piomelli,et al. A neuroscientist's guide to lipidomics , 2007, Nature Reviews Neuroscience.
[32] Eric Gouaux,et al. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters , 2007, Nature.
[33] J. W. Shaw,et al. Potential anti-inflammatory actions of the elmiric (lipoamino) acids. , 2007, Bioorganic & medicinal chemistry.
[34] V. Di Marzo,et al. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. , 2007, Experimental cell research.
[35] Q. Pittman,et al. Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret , 2007, The European journal of neuroscience.
[36] G. Bernardi,et al. N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors , 2007, Neuropsychopharmacology.
[37] P. Lory,et al. Chemical Determinants Involved in Anandamide-induced Inhibition of T-type Calcium Channels* , 2007, Journal of Biological Chemistry.
[38] C. Vaughan,et al. Actions of N-arachidonyl-glycine in a rat inflammatory pain model , 2007, Molecular pain.
[39] R. Vandenberg,et al. N‐Arachidonyl‐glycine inhibits the glycine transporter, GLYT2a , 2006, Journal of neurochemistry.
[40] Atsushi Inoue,et al. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. , 2006, Biochemical and biophysical research communications.
[41] H. Bradshaw,et al. Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[42] A. Saghatelian,et al. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. , 2006, Biochemistry.
[43] M. Oz. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. , 2006, Pharmacology & therapeutics.
[44] Y. Maor,et al. N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[45] R. Wolf,et al. Receptors for Protons or Lipid Messengers or Both? , 2006, Journal of receptor and signal transduction research.
[46] T. Bonnert,et al. Functional characterisation of the S512Y mutant vanilloid human TRPV1 receptor , 2005, British journal of pharmacology.
[47] A. Gerber,et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders , 2005, Journal of leukocyte biology.
[48] D. Kendall,et al. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. , 2005, European journal of pharmacology.
[49] A. Saghatelian,et al. Assignment of endogenous substrates to enzymes by global metabolite profiling. , 2004, Biochemistry.
[50] E. Butelman,et al. Antiallodynic Effects of Loperamide and Fentanyl against Topical Capsaicin-Induced Allodynia in Unanesthetized Primates , 2004, Journal of Pharmacology and Experimental Therapeutics.
[51] D. Merkler,et al. Oleic acid derived metabolites in mouse neuroblastoma N18TG2 cells. , 2004, Biochemistry.
[52] V. Di Marzo,et al. Actions of two naturally occurring saturated N‐acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels , 2004, British journal of pharmacology.
[53] R. Vandenberg,et al. Zn2+ Inhibits Glycine Transport by Glycine Transporter Subtype 1b* , 2004, Journal of Biological Chemistry.
[54] G. Czéh,et al. Direct evidence for activation and desensitization of the capsaicin receptor by N-oleoyldopamine on TRPV1-transfected cell, line in gene deleted mice and in the rat , 2004, Neuroscience Letters.
[55] S. Ikeda,et al. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. , 2004, Molecular pharmacology.
[56] D. Kendall,et al. Characterisation of the vasorelaxant properties of the novel endocannabinoid N‐arachidonoyl‐dopamine (NADA) , 2004, British journal of pharmacology.
[57] M. Raisinghani,et al. Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. , 2004, Journal of neurophysiology.
[58] A. Minassi,et al. A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. , 2004, Biochemical and biophysical research communications.
[59] D. Lovinger,et al. G Protein-coupled Endothelial Receptor for Atypical Cannabinoid Ligands Modulates a Ca2+-dependent K+ Current* , 2003, Journal of Biological Chemistry.
[60] E. Butelman,et al. Topical Capsaicin-Induced Allodynia in Unanesthetized Primates: Pharmacological Modulation , 2003, Journal of Pharmacology and Experimental Therapeutics.
[61] G. Ahern. Activation of TRPV1 by the Satiety Factor Oleoylethanolamide* , 2003, Journal of Biological Chemistry.
[62] B. Nilius,et al. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels , 2003, Nature.
[63] L. Petrocellis,et al. N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia* , 2003, The Journal of Biological Chemistry.
[64] R. Vandenberg,et al. Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a , 2003, Journal of neurochemistry.
[65] J. Walker,et al. Regulation of anandamide tissue levels by N-arachidonylglycine. , 2002, Biochemical pharmacology.
[66] L. Marnett,et al. Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. , 2002, Biochemical and biophysical research communications.
[67] Pierangelo Geppetti,et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[68] David Julius,et al. Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers , 2002, Cell.
[69] P. Lory,et al. Direct inhibition of T‐type calcium channels by the endogenous cannabinoid anandamide , 2001, The EMBO journal.
[70] J. Walker,et al. Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain* , 2001, The Journal of Biological Chemistry.
[71] A. Rittenhouse,et al. Arachidonic acid reversibly enhances N-type calcium current at an extracellular site. , 2001, American journal of physiology. Cell physiology.
[72] A. Rittenhouse,et al. Arachidonic acid both inhibits and enhances whole cell calcium currents in rat sympathetic neurons. , 2001, American journal of physiology. Cell physiology.
[73] T. Bisogno,et al. Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. , 2001, Bioorganic & medicinal chemistry letters.
[74] L. Petrocellis,et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. , 2000, The Biochemical journal.
[75] T. Bisogno,et al. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.
[76] B. Yagen,et al. Oxidative metabolism of anandamide. , 2000, Prostaglandins & other lipid mediators.
[77] T. Bonner,et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[78] Z. Vogel,et al. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. , 1997, Journal of medicinal chemistry.
[79] Stephen P. Mayfield,et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.
[80] J. Schwartz,et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.
[81] S. Bevan,et al. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region". , 1993, Journal of medicinal chemistry.
[82] S. Bevan,et al. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region". , 1993, Journal of medicinal chemistry.
[83] D. Gibson,et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.
[84] U. Sankawa,et al. Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives. , 1992, Chemical & pharmaceutical bulletin.